Biotech News

Message from the CEO to MediciNova Shareholders

MediciNova (MNOV)MediciNova2026-06-25 13:46 ESTCompany update

Strengthening MN-001’s Scientific Foundation and Clinical Outlook LA JOLLA, Calif. , Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis , I would like to provide additional perspective on why this research

Open original release

Related news

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MNOVMediciNova2026-06-25 13:46 EST

2026 New Year’s Greetings from the CEO

MNOVMediciNova2026-06-25 13:46 EST

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

View all latest news

MediciNova

MediciNova is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

MNOVZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

MNOVZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

MNOVBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

MNOVGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

MNOVMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 1.36 USD
Market cap: 68.42M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States